Avidity Biosciences(RNA) - 2023 Q4 - Annual Results

Exhibit 99.1 Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights Avidity is on-track to initiate global Phase 3 HARBOR™ trial of AOC 1001 for DM1 in mid-2024 Company to share first-look at long-term efficacy and safety data from MARINA-OLE™ trial in people living with DM1 at MDA Clinical & Scientific Conference and via webcast on March 4, 2024 Avidity to report data from clinical programs for people living with FSHD and DMD44 later this year SAN DIEGO, Feb. 2 ...